Prior to this position, Dr. Lu was a health economist in the biopharmaceutical industry for 2 decades, including nearly 17 years at Amgen, where he was a director of global health economics responsible for new drug pricing, reimbursement, and public policy. He is a co-author (with Prof. Stuart Schweitzer of UCLA) of an upcoming new book on pharmaceutical economics titled Pharmaceutical Economics and Policy: Perspectives, Problems, and Promises (3rd edition, Oxford University Press). His research interests extend to economics and policy issues affecting the industry worldwide.